Alnylam Pharmaceuticals (ALNY) shows strong price momentum, hitting new all-time highs on Aug. 11. ・ALNY has a 100% technical ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $406.0, a high ...

Despite battling drugs from BridgeBio and Pfizer, Amvuttra beat Wall Street expectations with results Alnylam’s CEO claimed were “not a flash in the pan.” ...

Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) shareholders will have a reason to smile today, with the analysts ...

Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 10 years ago, it would be worth $385.28 today based on a price of $433.41 for ALNY at the time of writing.

Company to Webcast Investor Event on August 30, 2025, at 1:00 p.m. EDT (7:00 pm CEST)- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that ...

Alnylam Pharmaceuticals (ALNY) shares surge 16% as it raises 2025 revenue outlook and posts strong Q3 results. Read more here.

Q2 2025 Earnings Call Transcript July 31, 2025 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Alnylam Pharma has an analyst consensus of Strong Buy, with a price target consensus of $317.10, a 18.95% upside from current levels. In a report released today, Scotiabank also maintained a Buy ...

Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $333.70. The stock’s 50 day moving average is $294.96 and its two-hundred day moving average is $266.07.

Contacts Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 ...